Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL252367 | 0.81 | TSHR (0.30) | TSHR | |
| SCHEMBL2522703 | 0.81 | TSHR (0.30) | TSHR | |
| SCHEMBL7081474 | 0.81 | TSHR (0.30) | TSHR | |
| SCHEMBL7858703 | 0.81 | TSHR (0.30) | TSHR | |
| SCHEMBL7262903 | 0.81 | TSHR (0.30) | TSHR | |
| SCHEMBL7948694 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL25380883 | 0.80 | — | — | |
| SCHEMBL7153188 | 0.79 | — | — | |
| SCHEMBL8817758 | 0.78 | — | — | |
| SCHEMBL14137010 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1012 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0977767-B1 | AMINOOXY-MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2007-09-19 | — | — | EP | claimed |
| JP-2003520042-A | — | — | 2003-07-02 | — | — | JP | claimed |
| EP-0977767-A4 | AMINOOXY-MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2003-04-23 | — | — | EP | claimed |
| EP-1250157-A1 | ANTISENSE MODULATION OF INDUCIBLE NITRIC OXIDE SYNTHASE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2002-10-23 | — | — | EP | claimed |
| WO-2001052902-A1 | ANTISENSE MODULATION OF INDUCIBLE NITRIC OXIDE SYNTHASE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | claimed |
| US-6194598-B1 | Aminooxy-modified oligonucleotide synthetic intermediates | ISIS PHARMACEUTICALS, INC. | 2001-02-27 | — | — | US | claimed |
| EP-0977767-A1 | AMINOOXY-MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2000-02-09 | — | — | EP | claimed |
| WO-1998035978-A9 | AMINOOXY-MODIFIED OLIGONUCLEOTIDES | — | 1999-01-14 | — | — | WO | claimed |
| WO-1998035978-A1 | AMINOOXY-MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1998-08-20 | — | — | WO | claimed |
| US-20260002157-A1 | MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250368996-A1 | MODIFIED ANTISENSE OLIGONUCLEOTIDES FOR TREATING HEPATITIS B VIRUS | ALIGOS THERAPEUTICS, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-12454691-B2 | Modified short interfering nucleic acid (siNA) molecules and uses thereof | ALIGOS THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250011789-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| CN-119032175-A | Modified spacer oligomers and methods of use thereof | 阿利戈斯治疗公司 | 2024-11-26 | — | — | CN | disclosed |
| US-6010906-A | NUCLEIC ACID HYBRID | ISIS PHARMACEUTICALS INC. (US) | 2000-01-04 | — | — | US | disclosed |
| US-5998603-A | TETRAHYDROFURANYL COMPOUNDS ARE PROVIDED THAT ARE FUNCTIONALIZED TO INCLUDE PENDANT CONJUGATE GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1998035978-A9 | AMINOOXY-MODIFIED OLIGONUCLEOTIDES | — | 1999-01-14 | — | — | WO | disclosed |
| WO-1998035978-A1 | AMINOOXY-MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1998-08-20 | — | — | WO | disclosed |
| US-5688941-A | Methods of making conjugated 4' desmethyl nucleoside analog compounds | ISIS PHARMACEUTICALS, INC. (US) | 1997-11-18 | — | — | US | disclosed |
| US-5608046-A | Conjugated 4'-desmethyl nucleoside analog compounds | ISIS PHARMACEUTICALS, INC. (US) | 1997-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011789-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, RNMT | TSHR 3325/4885 |
| US-20260002157-A1 | MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF | SRRT, SLIRP, FBL | TSHR 4191/4885 |
| US-20250368996-A1 | MODIFIED ANTISENSE OLIGONUCLEOTIDES FOR TREATING HEPATITIS B VIRUS | HAVCR2, SNRPB2, NSUN2 | TSHR 3437/4885 |
| US-12454691-B2 | Modified short interfering nucleic acid (siNA) molecules and uses thereof | SNRPA, SNRPA1, NSUN2 | TSHR 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.